Recordati Industria Chimica e Farmaceutica S.p.A.
RCDTFOTCHealthcare● Active
$60.00
+$0.00(+0.00%)
Market Cap$12.2B
P/E Ratio—
52W High$65.44
52W Low$55.88
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RCDTF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
$0.86
Revenue
$0.82B
Est. $0.82B · +0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
RCDTF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | — | — | — | — | $0.78B | — |
| — Q2 FY2026 | May 12, 2026 | — | $0.86 | — | $0.82B | $0.82B | +0.8% |
| ▲ Q1 FY2026 | Mar 31, 2026 | $0.86 | $0.88 | +2.7% | $0.78B | $0.78B | +0.0% |
| — Q4 FY2025 | Nov 11, 2025 | — | $0.93 | — | $0.74B | $0.77B | -4.0% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $0.90 | $0.82 | -9.0% | $0.76B | $0.76B | -0.3% |
| — Q2 FY2025 | May 8, 2025 | — | $0.88 | — | $0.75B | $0.74B | +1.3% |
| — Q1 FY2025 | Feb 13, 2025 | — | $0.39 | — | $0.62B | $0.60B | +2.7% |
| ▼ Q4 FY2024 | Nov 8, 2024 | $0.76 | $0.74 | -2.3% | $0.61B | $0.62B | -0.9% |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026
EPS Actual
$0.86
EPS Est.
—
EPS Surpr.
—
Revenue
$0.82B
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
$0.88
EPS Est.
$0.86
EPS Surpr.
+2.7%
Revenue
$0.78B
Q4 FY2025
Nov 11, 2025
EPS Actual
$0.93
EPS Est.
—
EPS Surpr.
—
Revenue
$0.74B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$0.82
EPS Est.
$0.90
EPS Surpr.
-9.0%
Revenue
$0.76B
Q2 FY2025
May 8, 2025
EPS Actual
$0.88
EPS Est.
—
EPS Surpr.
—
Revenue
$0.75B
Q1 FY2025
Feb 13, 2025
EPS Actual
$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.62B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
$0.74
EPS Est.
$0.76
EPS Surpr.
-2.3%
Revenue
$0.61B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.73 | $0.73 | $0.73 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.7B | $0.7B | $0.7B | 1 |
| Q3 FY2026 | $0.7B | $0.7B | $0.7B | 1 |
| Q2 FY2026 | $0.7B | $0.7B | $0.7B | 1 |
| Q1 FY2026 | $0.7B | $0.7B | $0.7B | 2 |
| Q4 FY2025 | $0.7B | $0.7B | $0.7B | 3 |
| Q3 FY2025 | $0.6B | $0.6B | $0.6B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 12, 2026 | — | $55.88 | $55.88 | +0.00% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +2.7% | $56.95 | $56.95 | +0.00% |
| — Q4 FY2025 | Nov 11, 2025 | — | $65.44 | $65.44 | +0.00% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -9.0% | $65.44 | $65.44 | +0.00% |
| — Q2 FY2025 | May 8, 2025 | — | $56.04 | $56.04 | +0.00% |
| — Q1 FY2025 | Feb 13, 2025 | — | $55.54 | $55.54 | +0.00% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -2.3% | $52.25 | $52.25 | +0.00% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +0.6% | $51.60 | $51.60 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 12, 2026
EPS Beat/Miss
—
Price Before
$55.88
Price After
$55.88
Q1 FY2026+0.00%
Report Date
Mar 31, 2026
EPS Beat/Miss
+2.7%
Price Before
$56.95
Price After
$56.95
Q4 FY2025+0.00%
Report Date
Nov 11, 2025
EPS Beat/Miss
—
Price Before
$65.44
Price After
$65.44
Q3 FY2025+0.00%
Report Date
Jul 30, 2025
EPS Beat/Miss
-9.0%
Price Before
$65.44
Price After
$65.44
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
—
Price Before
$56.04
Price After
$56.04
Q1 FY2025+0.00%
Report Date
Feb 13, 2025
EPS Beat/Miss
—
Price Before
$55.54
Price After
$55.54
Q4 FY2024+0.00%
Report Date
Nov 8, 2024
EPS Beat/Miss
-2.3%
Price Before
$52.25
Price After
$52.25
Q3 FY2024+0.00%
Report Date
Jul 30, 2024
EPS Beat/Miss
+0.6%
Price Before
$51.60
Price After
$51.60
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RCDTF ends December
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $0.86 (in line with the analyst consensus of —). The next RCDTF earnings date is expected around September 1, 2026.
Each quarter, investors track RCDTF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RCDTF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RCDTF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RCDTF earnings · 4 questionsRecordati Industria Chimica e Farmaceutica S.p.A.'s next earnings report is expected around September 1, 2026. RCDTF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RCDTF historically reports after market close (AMC).
RCDTF earnings datewhen is RCDTF earningsRCDTF next earnings datewhen does RCDTF report earningsRCDTF earnings calendar
▸ Source: FMP · Recordati Industria Chimica e Farmaceutica S.p.A. SEC filings · US GAAP · Recordati Industria Chimica e Farmaceutica S.p.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026